Morning Watch: Low Float (Nasdaq: SXTP) Sees CEO Acquire 70k+ Shares In December (4 Potential Catalysts)

Hot to the touch, this Nasdaq profile made a major splash on Tuesday while demonstrating its explosive potential.

*Sponsored by 60 Degrees Pharmaceuticals, Inc. StockWireNews Morning Watch: Low Float (Nasdaq: SXTP) Sees CEO Acquire 70k+ Shares In December (4 Potential Catalysts) December 11th Greetings Readers, Hot to the touch, this Nasdaq profile made a major splash on Tuesday while demonstrating its explosive potential. Why does it have explosive potential? For one, it has a low, low float or roughly 1.5Mn shares. When a profile has a float with such few shares available, the heightened potential for volatility will be ever-present on a daily basis. Plus, the company's CEO appears to be extremely bullish on his company's future as he recently scooped up over 70k shares in December. Mix in an analyst $3.40 target suggesting strong upside potential from current levels, and it makes a lot of sense why you should consider this breakout idea for your radar: *60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)* 60 Degrees Pharmaceuticals, Inc. specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. The company also collaborates with prominent research organizations in the U.S., Australia, and Singapore. Their mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional in-vest-ors including Knight Therapeutics Inc., a Canadian-based Pan-American specialty pharmaceutical company. And based on several potential breakout catalysts, SXTP has raced up my watchlist. Take a look: No. 1 - A Tiny Float Could Create A Volatile Situation (In Moments...). No. 2 - The CEO Appears To Be Bullish On SXTP With Recent Acquisition(s). No. 3 - An Analyst Target Suggests Approximately Triple-Digit Potential Upside From Tuesday Afternoon Valuation. No. 4 - 60 Degrees Announces Promotional Pilot Program For ARAKODA® Ahead Of Expanded U.S. Launch. But more on those in a second... 60 Degrees Pharmaceuticals' Pipeline Of Infectious Disease Medicines & Indications 60 Degrees Pharmaceuticals—a growth-oriented specialty pharmaceutical company—is putting cutting-edge biological science and applied research to use in furthering therapies for the prevention and treatment of infectious diseases. Currently the pipeline covers promising clinical development programs for babesiosis, dengue and other viral illnesses. Fulfilling the Promise of ARAKODA By leveraging its successful completion of clinical development and FDA approval of ARAKODA® (tafenoquine) for malaria prevention and exclusive research and licensing agreements with the U. S. Army, and with promising new non-clinical and clinical data in hand, 60 Degrees Pharmaceuticals is seeking to evaluate the utility of tafenoquine for additional indications.

Treatment of Babesiosis Tafenoquine exhibits useful activity in animal models of babesiosis and according to case reports may have clinical utility in treatment of drug-resistant strains.* In collaboration with leading U.S. institutions, 60 Degrees Pharmaceuticals is planning a proof of concept clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. Treatment & Prevention Of Fungal Diseases In vitro and in vivo studies demonstrate that tafenoquine is effective for treatment and prevention of fungi such as Pneumocystis and yeasts at concentrations/doses that are clinically relevant.1,2* Pneumocystis remains an important pathogen in organ transplant patients for whom the current standard of care is sub-optimal in some patient segments.3 Many infections caused by yeasts such as Candida auris are refractory to standard of care medications such as azoles, amphotericin B, and echinocandins.2 Celgosivir 60 Degrees Pharmaceuticals is planning a clinical development campaign for the repositioning of celgosivir, a host-targeted glucosidase inhibitor that was developed separately by other sponsors for HIV and hepatitis C4, but never approved by regulators. Similar to other dengue antivirals, celgosivir has shown diminished activity in curing dengue infection in animal models when administered after animals become symptomatic. However, this issue was addressed by administering the same dose split into four doses per day rather than one or two doses per daty.5 Preliminary data suggest celgosivir may inhibit the replication of the virus that causes CV-19 in cell culture, the RSV virus in cell culture, and may protect the lungs from RSV infection in animals.*

Sources: Company Website. Company Presentation. ----- And mentioned above, SXTP has several key potential catalysts to watch for at this moment. Take a look here: No. 1 SXTP Potential Catalysts - A Tiny Float Could Create A Volatile Situation (In Moments...). According to info from the Yahoo Finance website, SXTP has an extremely low float. In fact, the website reports this profile to have approx. 1.5Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could more positive company news towards the end of 2024 provide a near term spark? ----- No. 2 SXTP Potential Catalysts - The CEO Appears To Be Bullish On SXTP With Recent Acquisition(s). In December of 2024, Geoffrey Dow, the Chief Economic Officer (CEO) of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP), made multiple share purchases of 17k shares or more of the company's st-ock. This move may catch the attention of market analysts as insider buying often signals confidence in the company's future prospects. Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®. Check out the full Form 4 here. ----- No. 3 SXTP Potential Catalysts - An Analyst Target Suggests Approximately Triple-Digit Potential Upside From Tuesday Afternoon Valuation. As of 2:00PM EST Tuesday, an Ascendiant Capital Markets analyst target of $3.40 was suggesting serious upside potential. In fact, there may be a growth potential of roughly 100% to that target from its 2:00PM EST valuation Tuesday! Here's some highlights from the report: Babesiosis trial proceeding apace: SXTP previously announced it has signed clinical trial agreements with Yale, Tufts, and Rhode Island Hospital to carry out the study of Tafenoquine to treat Babesiosis. The trial is expected to recruit between 24 to 33 patients before an interim analysis is conducted, with sufficient enrollment capacity planned to ensure all subjects are recruited before the end of the 2025 tick season. If all goes well, the company will file an NDA by Q2 of FY26. In related news, the company announced IRB approval for a clinical study of Tafenoquine for Babesiosis in immunocompromised patients with persistent Babesia microti. The goal of the study is to confirm findings of a Yale study which showed an 80% cure rate in immunocompromised patients given weekly doses of Tafenoquine. Company continues to develop go-to-market strategy for ARAKODA for Malaria: With its second indication (ARAKODA for Babesiosis) currently in phase II clinical trials, the company's primary revenue opportunity at the moment remains ARAKODA as a Malaria prophylactic. To wit, the company announced a 9-month marketing pilot with prescribing physicians designed to raise awareness of ARAKODA, as well as collect patient data which will assist in further US market expansion. The company is highlighting the fact that ARAKODA is the only new antimalarial in over a decade and is differentiated by broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile ----- No. 4 SXTP Potential Catalysts - 60 Degrees Announces Promotional Pilot Program For ARAKODA® Ahead Of Expanded U.S. Launch. 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company has commenced a nine-month promotional pilot to bring greater awareness of ARAKODA® (tafenoquine) and its benefits to patients and healthcare providers who prescribe it. ARAKODA (tafenoquine) is an antimalarial indicated for the prevention of malaria in patients aged 18 years and older. "This pilot is intended to provide valuable insight into how healthcare professionals view ARAKODA as an antimalarial, and how they make decisions around how and when to prescribe it," said 60 Degrees Pharmaceuticals, Inc., Chief Executive Officer and President, Geoffrey Dow. "The purpose of the pilot is to equip ourselves with data that will improve the success of a planned expanded U.S. sales effort in 2025." The pilot program includes inside, or virtual, sales representatives who will conduct outreach to prospective and current ARAKODA customers to promote the co-pay program and increase sales. Part of the pilot entails development of a co-pay assistance program to assist with out-of-pocket costs for people traveling to malaria-endemic regions. Usage data generated by such a program will further inform the Company on questions related to ARAKODA customer demographics, pricing, prescription trends, and how and where to focus promotional efforts to increase sales. ... Read the full article here. ----- (Nasdaq: SXTP) Recap - 4 Key Potential Catalysts No. 1 - A Tiny Float Could Create A Volatile Situation (In Moments...). No. 2 - The CEO Appears To Be Bullish On SXTP With Recent Acquisition(s). No. 3 - An Analyst Target Suggests Approximately Triple-Digit Potential Upside From Tuesday Afternoon Valuation. No. 4 - 60 Degrees Announces Promotional Pilot Program For ARAKODA® Ahead Of Expanded U.S. Launch. ----- Coverage is officially initiated on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP). I'll be in touch with updates as the week moves forward. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and StockWireNews ("SWN") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. The single member of SWN Media LLC owns and operates smallcapfirm . com ("SCF"), fierceinvestor . com ("FI"), and stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: www.stockwirenews.net/disclosure Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired by TD Media LLC for a period beginning on 12/10/2024 and ending on 12/11/2024 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds") to disseminate information about (SXTP:US) via digital communications. These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US). Neither SWN Media LLC or its member own shares of (SXTP:US). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and 60 Degrees Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 12/9/2024 and ending on 12/11/2024 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, we have been paid ninety-nine thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US). Neither TD Media LLC or its member owns shares of (SXTP:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/sxtp/ Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States